The MSReactor computerized cognitive battery correlates with the Processing Speed Test in relapsing-remitting multiple sclerosis.
Publication date: Available online 25 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Charmaine Yam, Daniel Merlo, Jim Stankovich, David Darby, Melissa Gresle, Tomas Kalincik, Trevor J Kilpatrick, Jeanette Lechner-Scott, Bruce Taylor, Michael Barnett, Helmut Butzkueven, Anneke van der Walt
Condition: Relapsing Remitting Multiple Sclerosis Intervention: Drug: Dimethyl Fumarate (DMF) Sponsor: Hikma Pharmaceuticals LLC Not yet recruiting
Paediatric-onset multiple sclerosis presents in childhood or adolescence with fatigue and depression common among those living with POMS.1 Fatigue and depression are often comorbid conditions that have been consistently shown to affect cognitive function, social adjustment and anxiety among younger cohorts.2 Improved health behaviours, including improved physical activity, have been suggested as potential mediators of fatigue and depression among POMS patients.
Publication date: Available online 12 July 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Chih-Chao Yang, Long-Sun Ro, Nai-Wen Tsai, Chou-Ching Lin, Wen-Nan Huang, Ching-Piao Tsai, Thy-Sheng Lin, Jen-Jen Su, Chin-Chang Huang, Rong-Kuo Lyu, Hsin-Hua Chen, Wei-Ju Lee, Po-Lin Chen, Audrey Yang
Publication date: October 2020Source: Multiple Sclerosis and Related Disorders, Volume 45Author(s): Negar Ramezani, Pourya Yarahmadi, Mohammad Alirezaei, Seyed Mohammad Forouzannia, Razieh Sadat Kazemi Mozdabadi, Hossein Rezaei Aliabadi, Mohammad Reza Gheini, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi
This article aims to alert the medical community and public health authorities to accumulating evidence on health benefits from sun exposure, which suggests that insufficient sun exposure is a significant public health problem. Studies in the past decade indicate that insufficient sun exposure may be responsible for 340,000 deaths in the United States and 480,000 deaths in Europe per year, and an increased incidence of breast cancer, colorectal cancer, hypertension, cardiovascular disease, metabolic syndrome, multiple sclerosis, Alzheimer’s disease, autism, asthma, type 1 diabetes and myopia. Vitamin D has long b...
Authors: Wang Y, Bhargava P Abstract On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl fumarate (DMF), was approved for the same indication on March 27, 2013. Prior to its approval, DRF did not undergo rigorous testing to determine its efficacy, as its active metabolite, monomethyl fumarate, is the same as that of DMF (bioequivalency). The efficacy, safety and tolerability of DMF have previously been demonstrated in a number of clinical tria...
Publication date: October 2020Source: Multiple Sclerosis and Related Disorders, Volume 45Author(s): Juichi Fujimori, Kengo Uryu, Kazuo Fujihara, Mike P. Wattjes, Chihiro Suzuki, Ichiro Nakashima
Publication date: October 2020Source: Pharmacological Research, Volume 160Author(s): Silvia Pontis, Francesca Palese, Maria Summa, Natalia Realini, Massimiliano Lanfranco, Claudia De Mei, Daniele Piomelli
AbstractThe proinflammatory cytokine interleukin 1 (IL-1) is crucially involved in the pathogenesis of multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Herein, we studied the role of IL-1 signaling in blood –brain barrier (BBB) endothelial cells (ECs), astrocytes and microglia for EAE development, using mice with the conditional deletion of its signaling receptor IL-1R1. We found that IL-1 signaling in microglia and astrocytes is redundant for the development of EAE, whereas the IL-1R1 deletion in BB B-ECs markedly ameliorated disease severity. IL-1 signaling in BBB-ECs up...